Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2608 • ACR Convergence 2024
Evolution of Rheumatoid Arthritis Pharmacotherapy: A Ten-Year Analysis of Biologic and Targeted Synthetic DMARD Use and Its Predictors in a National Sample of Rheumatology Practices
Jing Li¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: The last decade has seen dramatic shifts in pharmacotherapy for rheumatoid arthritis (RA) with the increasing availability of biologic and targeted synthetic DMARDs (b/tsDMARDs).…
Abstract Number: 0237 • ACR Convergence 2024
Tofacitinib: A Retrospective Study on Safety and Adverse Effects
Vrushal Kale¹, Sandeep yadav², Canchi Balakrishnan³, Rohini Samant⁴, Bishakha Swain⁴, Shaurav Khanna⁵, Aashish Agrawal⁵ and Aditi Patankar⁴, ¹P D Hinduja national Hospital and medical Research centre, Mumbai, Maharashtra, India, ²Pd Hinduja hospital, Thane, Maharashtra, India, ³P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mahin, Maharashtra, India, ⁴P D Hinduja Hospital and Medical Research Centre, Mumbai, mumbai, Maharashtra, India, ⁵P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mumbai, Maharashtra, India
Background/Purpose: Tofacitinib, an oral Janus kinase inhibitor, is widely used in India to treat rheumatoid arthritis (RA) and other autoimmune diseases. Although its efficacy is…
Abstract Number: 0490 • ACR Convergence 2024
Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sebastian E. Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Massachusetts General Hospital, Winchester, MA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Bella Garg¹, John Antowan² and daniel Furst³, ¹Centinela Hospital Medical Center, Inglewood, CA, ²UCLA, Los Angeles, ³Pacific Arthritis Center, Inglewood
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
Abstract Number: 1456 • ACR Convergence 2024
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Lija James¹, Elnaz Saeedi², Jean-Guillaume Letarouilly¹, Nicola Gullick³, Anne Francis², Deepak Jadon⁴, William Tillett⁵, Yvonne Sinomati², Laura Tucker¹, Nadia Mian², Ines Rombach², Ioana Marian², Maria Sofia Massa² and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁴Cambridge University, Cambridge, United Kingdom, ⁵Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁶University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic musculoskeletal disease, which can lead to progressive joint pain, joint destruction, and loss of function. Evidence suggests that…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 2256 • ACR Convergence 2024
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
Jia Yi Hee¹, Hendrik Nel², Yann Abraham³, Katrina Chakradeo⁴, Michelle Roch⁴, Tom Lynch⁵, Lyn March⁵, Mihir Wechalekar⁶, Helen Keen⁷ and Ranjeny Thomas⁸, ¹The University of Queensland, Woolloongabba, Queensland, Australia, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Janssen Research and Development, Beerse, Belgium, ⁴The University of Queensland, Brisbane, Australia, ⁵The University of Sydney, Sydney, New South Wales, Australia, ⁶Flinders Medical Centre, Adelaide, Australia, ⁷Fiona Stanley Hospital, Murdoch, Western Australia, Australia, ⁸University of Queensland, Brisbane, Australia
Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
Abstract Number: 2611 • ACR Convergence 2024
Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial
Merel Opdam¹, Nathan den Broeder², Reinout van Crevel³, Lisa Schapink⁴, Léon Raijmakers⁴, Jasper Broen⁵, Lise Verhoef⁴ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ³Radboudumc, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Máxima Medical Centre, Eindhoven, Netherlands
Background/Purpose: Immunomodulatory agents (IA) are widely used for the treatment of inflammatory rheumatic diseases (IRDs). Although IA are safe and effective, management of infections and infection…
Abstract Number: 0238 • ACR Convergence 2024
Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Aljawharah Alrubayyi¹, Aaron Shulkin¹, Judith James², Meggan Mackay³, Dinesh Khanna⁴, Amit Bar-Or⁵, Susan Macwana⁶, Ellen Goldmuntz⁷, James McNamara⁸, Sean McCarthy⁹, Matthew Sherman⁸, William Barry¹⁰, Ashley Pinckney¹¹, Sarah Walker¹⁰, Sara Tedeschi¹², Jeffrey Sparks¹³, Zachary Wallace¹⁴ and Gaurav Gaiha¹⁵, ¹Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷NIAID/ NIH, Washington, DC, ⁸NIH, Bethesda, MD, ⁹DAIT/NIAID/NIH, Rockville, MD, ¹⁰Rho, Durham, NC, ¹¹Rho, St Louis Park, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ¹⁴Massachusetts General Hospital, Newton, MA, ¹⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Vaccines for SARS-CoV-2 have greatly reduced COVID-19 morbidity and mortality through the induction of neutralizing antibody responses. However, T cell responses are also induced…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Anisha Dua¹, Andrea Rubbert-Roth², Kerri Ford³, Stefano Fiore⁴, Lita Araujo³, Timothy Beukelman⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Northwestern University Division of Rheumatology, Chicago, IL, ²Cantonal Hospital St Gallen, St Gallen, Switzerland, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…
Abstract Number: 1331 • ACR Convergence 2024
Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
Sofia Pedro¹, Kristin Wipfler², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Patti Katz⁶ and Kaleb Michaud⁷, ¹Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Janssen, Chapel Hill, NC, ⁶UCSF, San Rafael, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Refractory rheumatoid arthritis (reRA) is characterized by an inadequate response to multiple DMARDs. Many factors including environment, comorbidities, sociodemographics, and the treatment itself influence poor…
Abstract Number: 1458 • ACR Convergence 2024
Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients
Pauline KRUG¹, angela De Sousa Leite², Frédéric Lecouvet¹, Maria Simona stoenoiu¹ and Adrien Nzeusseu Toukap³, ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires St-Luc, Brussels, Belgium, ³Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogeneous disease. The response to therapy is variable among patients (ref.). Therefore, we need a tailored approach. Biologic…
Abstract Number: 1757 • ACR Convergence 2024
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Walter Maksymowych¹, Sofia Ramiro², Denis Poddubnyy³, Xenofon Baraliakos⁴, Robert Lambert¹, Ute Massow⁵, Thomas Vaux⁶, Chetan Prajapati⁶, Alexander Marten⁵, Natasha de Peyrecave⁷ and Mikkel Ostergaard⁸, ¹University of Alberta, Edmonton, AB, Canada, ²Leiden University Medical Center, Bunde, Netherlands, ³Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: The impact of bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, on structural lesions in patients (pts)…

« Previous Page
1
…
4
5
6
7
8
…
40
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].